Credit Suisse Group Reiterates GBX 6,350 Price Target for AstraZeneca (LON:AZN)

Credit Suisse Group set a GBX 6,350 ($82.97) price objective on AstraZeneca (LON:AZN) in a research note published on Friday, March 29th, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other reports. Barclays reissued an overweight rating on shares of AstraZeneca in a research report on Tuesday, February 5th. Deutsche Bank reissued a buy rating and issued a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research report on Tuesday, March 5th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research note on Monday, February 25th. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) price target on AstraZeneca and gave the stock a buy rating in a report on Tuesday, January 29th. Finally, Goldman Sachs Group set a GBX 4,080 ($53.31) price target on AstraZeneca and gave the stock a sell rating in a report on Thursday, February 14th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of GBX 6,362.70 ($83.14).

Shares of LON AZN traded down GBX 99 ($1.29) during trading hours on Friday, reaching GBX 5,815 ($75.98). The stock had a trading volume of 2,258,433 shares, compared to its average volume of 2,310,000. The stock has a market cap of $76.28 billion and a PE ratio of 34.21. The company has a quick ratio of 0.71, a current ratio of 0.96 and a debt-to-equity ratio of 136.31. AstraZeneca has a fifty-two week low of GBX 4,928.50 ($64.40) and a fifty-two week high of GBX 6,540 ($85.46).

The firm also recently disclosed a dividend, which was paid on Wednesday, March 27th. Investors of record on Thursday, February 28th were issued a GBX 146.80 ($1.92) dividend. This is a positive change from AstraZeneca’s previous dividend of $68.40. This represents a yield of 2.57%. The ex-dividend date was Thursday, February 28th. AstraZeneca’s dividend payout ratio is currently 1.26%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.